The 2015 established European Nanomedicine Characterisation Laboratory (EU-NCL) aims at providing critical infrastructure and characterisation services that are needed to analyse physical and chemical attributes, in vitro biological properties, and in vivo characteristics of emerging nanomedicines ready for translation and clinical trials. The current call welcomes proposals for the pre-clinical characterisation of medical nanoparticles with the objective to expedite the development and translation towards clinical use. The first characterisation campaign is dedicated to medicinal nanoparticles based on organic compounds with proposed application in cancer treatment and/or diagnosis via the intravenous route. The submission deadline for the first campaign is 15th April  2016.


The EUNCL offers a comprehensive assay cascade aimed at evaluating the quality and safety of your nanomaterial. Moreover, the EUNCL will supply sponsors with a complete and detailed characterisation data set that enables researchers in academia, industry, and government to facilitate further development and translation of their nanotechnology strategies towards clinical applications. If a project is selected, the EUNCL's services will be provided at no cost to the submitting sponsor.





Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.